SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

azetukalner

XENE·Xenon Pharmaceuticals Inc.
MIXED
Drug Impact Rating7/10
Trial phase
Filed/NDA under FDA review
Time to market
If the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.
Why 7/10
The next hard catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA (submitted Sept 17, 2026), expected around mid-November 2026. If accepted, a PDUFA date would be set. Azetukalner is Xenon's only late-stage asset and essentially the entire company value driver, but the psychiatry program pause has created significant overhang, capping the impact score.
Actionable Insight MIXED

The next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.

Price Chart

Loading chart...

Executive Summary

Azetukalner (XEN1101) is a novel KV7 potassium channel opener being developed by Xenon Pharmaceuticals (XENE) for epilepsy and psychiatric disorders. The drug produced strong Phase 3 data in focal onset seizures (53.2% median seizure reduction at 25mg vs 10.4% placebo, p<0.0001), and an NDA was submitted to the FDA on September 17, 2026. However, the company simultaneously paused enrollment in Phase 3 depression trials after neuropsychiatric adverse events including psychosis emerged, causing the stock to crash 30% in a single day. The stock now trades at $39.19, well off its 52-week high of $72.66, with analyst consensus at Strong Buy and a mean price target of $71.75. The next catalyst is the FDA's 60-day filing acceptance decision, expected around mid-November 2026.

How It Works

Azetukalner is a KV7 potassium channel opener. It works by opening specific potassium channels on the surface of neurons, which helps stabilize the electrical activity of brain cells and makes them less likely to fire abnormally. This dampens the excessive, synchronized electrical activity that causes seizures. It is taken as a once-daily oral pill.

Trial Status

The Phase 3 X-TOLE2 trial (n=380) in focal onset seizures met its primary endpoint with high statistical significance. An NDA was submitted to the FDA on September 17, 2026. Two additional Phase 3 epilepsy trials (X-TOLE3 in focal seizures, X-ACKT in primary generalized tonic-clonic seizures) continue to enroll. Three Phase 3 psychiatry trials (X-NOVA2 in MDD, X-CEED in bipolar depression) had new enrollment paused in September 2026 due to neuropsychiatric adverse events; existing patients continue in the studies.

The Two-Sided Case

▲ Bull Case6
The Phase 3 X-TOLE2 trial delivered strong results: 53.2% median seizure reduction at 25mg vs 10.4% for placebo (p<0.0001), one of the largest placebo-adjusted efficacy signals seen in recent epilepsy trials.
The NDA for focal seizures was submitted to the FDA on September 17, 2026, backed by over 1,500 patient-years of epilepsy safety data across two positive trials.
Analyst consensus is Strong Buy (11 Strong Buy, 12 Buy, 2 Hold) with a mean price target of $71.75, implying 83% upside from the current $39.19 price.
Insider buying at ~$37.38/share in late September 2026: CEO Ian Mortimer purchased $1.12M worth and CFO Thomas Patrick Kelly purchased $560K worth, signaling confidence near current levels.
Xenon holds $1.245B in cash (as of June 30, 2026), funding operations into 2029 with no near-term financing risk.
If approved, azetukalner would be the first KV7 potassium channel opener available for epilepsy, a novel mechanism of action with no direct approved competitor.
▼ Bear Case5
The psychiatry program (MDD and bipolar depression) was paused in September 2026 after neuropsychiatric adverse events including psychosis were observed, which wiped 30% off the stock in a single day and casts a shadow over the broader azetukalner safety profile.
Deutsche Bank downgraded the stock from Buy to Hold on Sept 18, 2026, and several large institutional holders trimmed or exited in Q2 2026, including Wellington Management (trimmed 70.5%), Holocene Advisors (exited), and Jennison Associates (near-exit, trimmed 84.2%).
Elevated short-sale volume (z-score 1.51 vs the stock's own history) suggests bearish positioning around the stock.
The company has no approved products and is a single-asset biotech; any FDA setback on the NDA would be devastating.
The stock trades at $39.19, down 46% from its 52-week high of $72.66, reflecting deep market skepticism about the psychiatry setback.

Upcoming Catalysts

  • FDA 60-day filing acceptance decision on the azetukalner NDA (expected mid-November 2026)
  • Q3 2026 earnings call on November 9, 2026 (business update, psychiatry program update)
  • Potential PDUFA date assignment if NDA is accepted for filing
  • X-TOLE3 and X-ACKT Phase 3 epilepsy trial enrollment completion updates
  • X-NOVA2 MDD topline data (previously expected H1 2027, but timeline uncertain due to enrollment pause)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xenon Pharmaceuticals Inc. PRESS-RELEASE XENE ·Originating report

Sources · 15

Hover a chip for the title
1 investor.xenon-pharma.com2 investor.xenon-pharma.com3 jamanetwork.com4 biospace.com5 rttnews.com6 fiercebiotech.com7 novapharmanews.com8 investor.xenon-pharma.com9 fool.com10 neurologylive.com11 neurologylive.com12 marketchameleon.com13 marketchameleon.com14 onlinelibrary.wiley.com15 pubmed.ncbi.nlm.nih.gov